Search

Meet our new member CIMAB. We spoke with Agustín García-Peiró, CEO and Founder.

Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical

Personalized medicine is no longer a promise—it's a reality, with genetics as its key ally. To bring this knowledge into everyday clinical practice, N·GENE was created: a platform that translates

BCN HEALTH has published the study ‘Hepatocellular carcinoma: what are the differential costs compared to the general population?’ in the Journal of Medical Economics, a peer-reviewed journal

Join our free event on Tuesday, July 8th at the Parque Científico de Barcelona for an extended version of our Lunch and Learn series where we will introduce the diverse capabilities of Schrödinger’s

The award recognises the company's track record, innovation and contribution to the economic and social development of Extremadura.

Meet our new member Microviable Therapeutics . We sponke with Claudio Hidalgo Cantabrana, CEO.

The webinar exploring the in-vitro ADME (Absorption, Distribution, Metabolism, and Excretion) properties of peptide therapeutics.

The 86 spin-offs, start-ups and scale-ups operating in the PCB collectively secured €124.7 million in funding in 2024, which is a substantial rise on the €85.4 million raised in 2023.

Interview with Mireia Forner, Medical Head of Neurology at Sanofi Iberia, a company working to change how multiple sclerosis is understood and treated.

We demonstrated that our assay could detect residual disease in AML patients after treatment with 92% sensitivity and 88% specificity—a significant leap forward compared to traditional monitoring

AseBio stands as the only sectoral organization represented in this body, alongside the digital sector, highlighting the recognition of biotechnology as a strategic sector within the field of emerging

Schrödinger will host a scientific workshop in Barcelona on July 8 to showcase how its molecular design platform leverages physics-based simulation and machine learning to accelerate drug discovery.

Bioga and five Galician biotech companies joined Swiss Biotech Day 2025, one of Europe’s leading life sciences events, to foster connections and explore partnerships with Swiss firms—highlighting

BCN HEALTH will participate in the Jornadas de la Asociación de Economía de la Salud (AES), which will take place in Madrid from June 18 to 20, with the presentation of two communications focused on

AseBio partners are leading the shift towards a more sustainable agri-food system, combining biotechnology, artificial intelligence, and regenerative practices to ensure safe and affordable food for